MARKET

CANF

CANF

Can Fite Biophar
AMEX

Real-time Quotes | Nasdaq Last Sale

0.8710
-0.0187
-2.11%
Pre Market: 0.8623 -0.0087 -1.00% 05:52 05/25 EDT
OPEN
0.8734
PREV CLOSE
0.8897
HIGH
0.9118
LOW
0.8530
VOLUME
15
TURNOVER
--
52 WEEK HIGH
2.620
52 WEEK LOW
0.7800
MARKET CAP
23.68M
P/E (TTM)
-1.0558
1D
5D
1M
3M
1Y
5Y
BRIEF-Can-Fite Granted Key Nash Patent In Israel
reuters.com · 05/16 11:10
Can-Fite Granted Key NASH Patent In Israel
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its patent
Benzinga · 05/16 11:01
Can-Fite Biopharma Awarded Patent in Israel for Liver Disease Treatment Method
MT Newswires · 05/16 10:22
Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
PETACH TIKVA, Israel, May 02, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Compa...
Business Wire · 05/02 11:00
Can-Fite reports positive data from preclinical trial of topical psoriasis treatment
Can-Fite (NYSE:CANF) said it was developing a topical psoriasis treatment with its psoriasis oral drug candidate Piclidenoson. The Company’s said that in a preclinical trial, daily treatment with topical Piclidenoson
Seekingalpha · 04/05 16:20
Can-Fite Biopharma Developing Psoriasis Treatment With Drug Candidate Piclidenoson
MT Newswires · 04/05 13:48
Can-Fite Says Is Developing A Topical Piclidenoson Psoriasis Treatment That Shows Efficacy In Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
Topical psoriasis treatments account for 42% of the $11.37 billion psoriasis drug market Topline results from Phase III oral Piclidenoson study expected Q2 2022 Piclidenoson has been
Benzinga · 04/05 11:07
Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
PETACH TIKVA, Israel, April 05, 2022--Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model
Business Wire · 04/05 11:00
More
No Data
Learn about the latest financial forecast of CANF. Analyze the recent business situations of Can Fite Biophar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CANF stock price target is 5.85 with a high estimate of 8.25 and a low estimate of 5.00.
High8.25
Average5.85
Low5.00
Current 0.8710
EPS
Actual
Estimate
-0.26-0.22-0.19-0.15
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 9
Institutional Holdings: 356.04K
% Owned: 1.31%
Shares Outstanding: 27.19M
TypeInstitutionsShares
Increased
1
33.68K
New
3
224.94K
Decreased
4
5
Sold Out
1
913
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Director
Ilan Cohen
Chief Executive Officer/Director
Pnina Fishman
Chief Financial Officer/Chief Operating Officer
Motti Farbstein
Director
Golan Bitton
Director
Guy Regev
Director
Abraham Sartani
Director
Israel Shamay
No Data
No Data
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Webull offers kinds of Can Fite Biopharma Ltd stock information, including AMEX:CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.